Search

Changes to Formulary as of 11th October 2018:

BNF Category Number

Product/indication

Detail of change

14.4

HPV Vaccine (Gardasil®)

Added as a Green drug and deleted Cervarix brand

3.4.3.1

Adrenaline auto-injector

Added Emerade® as another option

4.4

Guanfacine

Changed from RED to AMBER and added link to TEWV Shared Care

11

 

Updated formulary chapter added

6.1.1

Humulin R insulin

Deleted from formulary

13.2.1.1

Emollient bath additives

Deleted from formulary

13.4

Steroid creams containing antimicrobials

·      Trimovate – removed from formulary due to ongoing supply issues

·      Highlighted pack sizes that are available OTC

·      Added Fucibet®, Synalar N®, Synalar C® and Lotriderm® to formulary as cheaper than current potent steroid choices.

·      Betamethasone 0.1% with clioquinol 3%, Betamethasone 0,1% with neomycin 0.5%,  Fucidin H®, Nystaform HC®, Terra-Cortil® and Dermovate NN® make second line due to cost.

8.2.2

Tacrolimus (oral) for non-transplant indications

Changed from AMBER to RED

4.7.2

Buprenorphine 35microgram/hr, 52.5microgram/hr &

70microgram /hr 96 hour patches

Added as GREEN ALTERNATIVE

1.2.2

Mebeverine Liquid

Annotated as 2nd line after tablets

6.4.1.2

Ulipristal acetate 5mg tablets (Esyma®)

Changed from GREEN+ to RED

6.6.2.2

Denosumab (Xgeva▼) for giant cell tumour of bone: risk of clinically significant hypercalcaemia following discontinuation

Added link to MHRA DSU Guidance

6.6.2.2

Denosumab (Xgeva▼) for advanced malignancies involving bone: study data show new primary malignancies reported

more frequently compared to zoledronate

Added link to MHRA DSU Guidance

5.3.1

Darunavir boosted with cobicistat:

avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1

Added link to MHRA DSU Guidance

3

Pressurised metered dose inhalers (pMDI): risk of airway obstruction from aspiration of loose objects

Added link to MHRA DSU Guidance

5.2

Parenteral amphotericin B: reminder of risk of potentially fatal adverse reaction if formulations confused

Added link to MHRA DSU Guidance

8.1.5

Pembrolizumab

Added link to NICE TA522

8.1.5

Midostaurin

Added as a RED drug and added link to NICE TA523

8.1.5

Brentuximab vedotin

Added link to NICE TA524

8.2.4

Atezolizumab

Added link to NICE TA525

8.2.4

Arsenic trioxide

Added link to NICE TA526

8.2.4

Beta interferons and glatiramer acetate

Added link to NICE TA527

8.2.4

Niraparib

Added link to NICE TA528

8.1.5

Crizotinib

Added link to NICE TA529

8.2.4

Nivolumab

Added link to NICE TA530

8.1.5

Pembrolizumab

Added link to NICE TA531

8.2.4

Ocrelizumab

Added link to NICE TA533

4.11

NICE NG97

Added link to chapter 4.11

10

NICE NG100

Added link to start of chapter 10

9.6.7

Vitamin supplements for eye

degeneration (e.g. Macushield)

Added as NOT APPROVED

BNF Category Number

Product/indication

Detail of change

6.5.2.2

Tolvaptan 

Entry on the formulary should be updated  as per the NoT/Tees formulary.

6.1

Insulin Aspart (Fiasp)

Added as RED drug and added link to MHRA letter to HCP

8.2.3

Avelumab

Added as RED drug and added link to NICE TA517

10.1.3

Tocilizumab

Added link to NICE TA518

8.1

Pembrolizumab

Added link to NICE TA518

8.1

Atezolizumab

Added link to NICE TA519

13.5

Guselkumab

Added link to NICE TA521

5.1.9

Ethambutol

400mg in 5ml added as green

5.1.9

Pyrazinamide

500mg in 5ml added as green

5.1.9

Isoniazid

50mg in 5ml added as green

2.5.1

Sildenafil

Added as a RED drug for Raynaud's

7.3.2.3

Levosert

License change from 3 to 4 years

3.2

Seretide evohaler and accuhaler

Removed from formulary

3.2

Fobumix

Added as GREEN drug

3.2

Sereflo

Added as GREEN drug

1.9.1

Obeticholic Acid

Added link to MHRA DSU Guidance

4.8.1, 4.7.4.2, 4.2.3

Sodium valproate

Added links to MHRA DSU Guidance

3.1.2

Tiotropium (Braltus)

Added link to MHRA DSU Guidance

6.1.1.2

Insulin Degludec

Added link to MHRA letter to HCP

15

 

New formulary chapter added